Funding Opportunity Purpose:
Through this ‘I-Corps at NIH‘ program Funding Opportunity announcement (FOA), the NIH & Center for Disease Control and Prevention (CDC) provide administrative suppliment awards to ACTIVE SBIR (NIH & CDC) and STTR PHI (NIH only Recipients. The I-Corps at NIH program is focused on educating reseachers and technologists on how to translate technologies from the lab to the marketplace. I-Corps enables and accelerates the transformation of invention to impact patients.
The program provides three-member projet teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH & CDC SBIR & STTR funding. The participantes conduct evidence-based research to identify where the company’s technology can have the greatest impct on unment clinical needs. it is anticipated the outcomes for the I-Corps teams participating in this progra will include significantly refines commercialization plans and well-informed pivots in their overall commercialization atrategies. Prospective applicants are STRONGLY ENCOURAGED to contact relevant Scientific/Research staff listed in Section VII of the FA for more information about the program, befor applying.
The I-Corps at NIH provides funding, mentoring, and networking opportunities to current Phase I SBIR/STTR awardees and Fast-Track awardees in the first phase of their award to help commercialize promising biomedical technologies. In this 8-week, hands-on program, you’ll learn how to identify customer needs and get the tools to bring your innovation to those patients who most need it. Program benefits include:
- Funding up to $55,000 to cover total program costs;
- Training from biotech sector experts;
- Ability to expand your professional network;
- Opportunity to build confidence and skills to develop a comprehensive business model ; and,
- Gain years of entrepreneurial skills in a matter of weeks.
All applications must be submitted through PAR-22-073 no later than November 16th, 2022.
Other submission deadlines moving foward are: February 2, 2023; November 15, 2023; February 2, 2024 by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
It is critical that applicants follow the instructions in the Application Guide (SF424 (R&R) Application Guide, as appropriate) except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Testimonials from previous participants may be found in archived webinar recordings: https://sbir.cancer.gov/programseducation/icorps/webinar.
Please thoroughly read the FOA PAR-22-073 at the link. All agency contact information is provided in the FOA. Again, prospective applicants are STRONGLY ENCOURAGED to contact relevant Scientific/Research staff listed in Section VII of the FA for more information about the program, befor applying.